Clinical Trial

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Protocol Amendment History 2 changes
notable Trial sites expanded: 7 -> 11 locations 2026-06-13
notable Trial sites expanded: 3 -> 7 locations 2026-05-23
Trial Details
NCT Number NCT07271667
Lead Sponsor Curis, Inc.
Conditions Chronic Lymphocytic Leukemia, B-cell Malignancies
Enrollment 108 participants
Start Date 2026-04-23
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-12